FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Nur für Forschungszwecke. Vollständige Erklärung →

Peptidebibliothek

Dermorphin

Dermorph

Fat Loss & Body Composition

Dermorphin is a naturally occurring seven-amino acid opioid peptide (Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2) first isolated from the skin secretions of South American tree frogs of the genus Phyllomedusa. It is approximately 30-40 times more potent than morphine as a mu-opioid receptor agonist and contains the unusual D-alanine residue at position 2, making it one of the first discovered naturally occurring D-amino acid-containing peptides. It has gained notoriety for its illegal use in horse racing as a performance enhancer and pain masking agent.

Wirkmechanismus

Naturally occurring heptapeptide isolated from the skin of South American tree frogs (Phyllomedusa). Potent and selective mu-opioid receptor agonist — approximately 30-40 times more potent than morphine. Contains D-alanine, which is rare in natural peptides.

Forschungsprotokolle

Nur für Forschungszwecke. Keine medizinische Beratung.

Not recommended for human research due to extreme potency and opioid receptor agonism. Primarily of academic interest. Studied in pharmacological research for understanding mu-opioid receptor selectivity.

Forschungsnotizen

Clinical Research Status

Dermorphin has not been developed for human clinical use and has no active clinical trials or regulatory filings for any therapeutic indication. Research has been confined to pharmacological characterization, opioid receptor binding studies, and development of detection methods for equine anti-doping enforcement. It serves primarily as a research tool for understanding mu-opioid receptor pharmacology and the evolution of bioactive peptides in amphibian defense secretions.

Key Published Findings

Binding studies demonstrate that dermorphin has exceptionally high selectivity and affinity for mu-opioid receptors (Ki approximately 0.2-1.6 nM), significantly exceeding morphine in both potency and selectivity. The D-alanine residue at position 2 confers resistance to aminopeptidase degradation, extending its biological half-life compared to L-amino acid-containing endogenous opioid peptides. Research on dermorphin and its analogs has contributed significantly to understanding structure-activity relationships at the mu-opioid receptor and has led to development of several research tools for opioid pharmacology.

Safety Profile

As an extremely potent mu-opioid agonist, dermorphin carries all the risks associated with opioid intoxication including respiratory depression, profound sedation, physical dependence, and potentially fatal overdose. No therapeutic index has been established for humans, and the steep dose-response curve of highly potent opioids makes accidental overdose a significant risk. The absence of human pharmacokinetic data means that dosing, onset, duration, and drug interactions are completely unknown in clinical contexts.

Comparison to Related Compounds

Dermorphin is significantly more potent than morphine (30-40x) and fentanyl-like in its receptor binding affinity, though it maintains high mu-selectivity unlike some synthetic opioids that have broader receptor profiles. Its natural analog deltorphin (from the same frog species) is similarly potent but selective for delta-opioid receptors rather than mu-receptors. Compared to endogenous opioid peptides (endorphins, enkephalins), dermorphin's D-amino acid content provides superior metabolic stability and greater pharmacological potency.

Community Observations

Dermorphin is primarily known in the public sphere through horse racing scandals, where it has been detected in post-race urine samples from winning horses in multiple US states including Louisiana, Oklahoma, and New Jersey. Its use in horse racing is considered animal abuse by regulatory bodies, as it masks pain and allows injured horses to race at risk of catastrophic breakdown. Human recreational use is extremely rare due to limited availability and the extreme danger posed by its potency, with the research community treating it primarily as a pharmacological tool rather than a potential therapeutic.

Halbwertszeit

~2-3 hours

Rekonstitution

Sterile saline

Lagerung

Lyophilisiert

Store at -20C.

Rekonstituierter

Refrigerate 2-8C. Use within 7 days.

Rechtsstatus USA

Not scheduled but DEA analog act may apply

Auch bekannt als

Dermorph

Häufig gestellte Fragen

Was ist Dermorphin?

Dermorphin is a naturally occurring seven-amino acid opioid peptide (Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2) first isolated from the skin secretions of South American tree frogs of the genus Phyllomedusa. It is approximately 30-40 times more potent than morphine as a mu-opioid receptor agonist and contains the unusual D-alanine residue at position 2, making it one of the first discovered naturally occurring D-amino acid-containing peptides. It has gained notoriety for its illegal use in horse racing as a performance enhancer and pain masking agent.

Wie wirkt Dermorphin?

Naturally occurring heptapeptide isolated from the skin of South American tree frogs (Phyllomedusa). Potent and selective mu-opioid receptor agonist — approximately 30-40 times more potent than morphine. Contains D-alanine, which is rare in natural peptides.

Wie ist der regulatorische Status von Dermorphin in den USA?

Not scheduled but DEA analog act may apply

Wie lang ist die Halbwertszeit von Dermorphin?

~2-3 hours

Wie wird Dermorphin noch genannt?

Dermorph

Peptide Contacts bietet wissenschaftliche Zusammenfassungen für informationstechnische Zwecke an. Wir stellen keine Dokumentationen von Anbietern, keine Host- und keine Vertriebsdienstleistungen zur Verfügung und unterstützen keine Anbieter in irgendeiner Weise. Alle Zertifikate der Analyse, GMP-Zertifikate und Kommunikationen mit Anbietern müssen direkt vom Käufer angefordert und überprüft werden. Alles auf dieser Plattform stellt weder rechtliche, medizinische noch berufsmäßige Beratung dar. Nutzer sind allein verantwortlich für die Überprüfung der Anbieterzertifikate und das Gewährleisten des Einhaltens aller anwendbaren lokalen, zuständigen und federalen Gesetze beim Kauf von Forschungschemikalien. Die Nutzung dieser Plattform bedeutet die Annahme volles persönlichen Verantwortlichkeitsbewusstseins.

Ganze Erklärung lesen